High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation.

Production of large quantities of highly purified plasmid DNA is essential for gene therapy. A low-copy-number pBR322-derived plasmid (VCL1005) was converted to a high-copy-number plasmid (VCL1005G/A) by incorporating a G-->A mutation that affects initiation of DNA replication from the ColE1 origin of replication. Because the phenotypic effect of this mutation is enhanced at an elevated temperature, a further increase in yield was achieved by changing the growth temperature from 37 degrees C to 42 degrees C at mid-log phase during batch and fed-batch fermentation. The combined effect of the single base-pair change and the elevated growth temperature produced an overall yield of 2.2 grams of plasmid DNA available for recovery from a 10-liter fed-batch fermentation compared to 0.03 grams from a 10-liter batch fermentation, a 70-fold increase in yield. The plasmid DNA isolated from this process contained lower levels of RNA and chromosomal DNA contaminants, simplifying downstream processing.

[1]  J. Vieira,et al.  The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. , 1982, Gene.

[2]  J. Tomizawa.  Control of ColE1 plasmid replication. Interaction of Rom protein with an unstable complex formed by RNA I and RNA II. , 1990, Journal of molecular biology.

[3]  F. Ledley.  Nonviral gene therapy: the promise of genes as pharmaceutical products. , 1995, Human gene therapy.

[4]  A. Lapidus,et al.  Use of a dual-origin temperature-controlled amplifiable replicon for optimization of human interleukin-1 beta synthesis in Escherichia coli. , 1991, Gene.

[5]  S. Lin-Chao,et al.  High copy number of the pUC plasmid results from a Rom/Rop‐suppressible point mutation in RNA II , 1992, Molecular microbiology.

[6]  J. Davison.  Mechanism of control of DNA replication and incompatibility in ColE1-type plasmids--a review. , 1984, Gene.

[7]  H. Boyer,et al.  Genetic and physical studies on the replication of ColE1-type plasmids. , 1979, Cold Spring Harbor symposia on quantitative biology.

[8]  V. Sondak,et al.  Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. , 1993, Cancer research.

[9]  G. Pósfai,et al.  High-copy-number derivatives of the plasmid cloning vector pBR322. , 1984, Gene.

[10]  Chuan Yi Tang,et al.  A 2.|E|-Bit Distributed Algorithm for the Directed Euler Trail Problem , 1993, Inf. Process. Lett..

[11]  J. Davison,et al.  Vectors with restriction-site banks. I. pJRD158, a 3903-bp plasmid containing 28 unique cloning sites. , 1984, Gene.

[12]  M. Furuno,et al.  Construction of a plasmid vector for the regulatable high level expression of eukaryotic genes in Escherichia coli: an application to overproduction of chicken lysozyme. , 1987, Protein engineering.

[13]  T. Ritch,et al.  Production of human alpha consensus interferon in recombinant Escherichia coli , 1986 .

[14]  F. Bolivar,et al.  Construction and characterization of new cloning vehicles. I. Ampicillin-resistant derivatives of the plasmid pMB9. , 1977, Gene.

[15]  G W Luli,et al.  Comparison of growth, acetate production, and acetate inhibition of Escherichia coli strains in batch and fed-batch fermentations , 1990, Applied and environmental microbiology.

[16]  A. Kahru,et al.  Glucose-limited fed-batch cultivation of Escherichia coli with computer-controlled fixed growth rate. , 1990, Biotechnology and bioengineering.

[17]  S. Parker,et al.  Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. , 1995, Human gene therapy.

[18]  E. Nabel,et al.  Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Denéfle,et al.  High-cell density fermentation studies of recombinant Escherichia coli strains expressing human interleukin-1β , 1988 .

[20]  D. Sherratt,et al.  Trans-complementable copy-number mutants of plasmid ColE1 , 1980, Nature.

[21]  C. Yanisch-Perron,et al.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. , 1985, Gene.

[22]  A. Chang,et al.  Immunotherapy of malignancy by in vivo gene transfer into tumors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  N. Minton,et al.  Improved plasmid vectors for the isolation of translational lac gene fusions. , 1984, Gene.

[24]  F. Bolivar,et al.  Plasmid vector pBR322 and its special-purpose derivatives--a review. , 1986, Gene.

[25]  M. Robinson,et al.  Dual-origin plasmid vectors whose origin of replication is controlled by the coliphage lambda promoter pL. , 1984, Gene.

[26]  D. Clewell,et al.  Nature of Col E1 Plasmid Replication in Escherichia coli in the Presence of Chloramphenicol , 1972, Journal of bacteriology.

[27]  N. Panayotatos.  DNA replication regulated by the priming promoter. , 1984, Nucleic acids research.

[28]  A. Stopeck,et al.  Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. , 1996, Cancer gene therapy.

[29]  M. Helmer-Citterich,et al.  Control of ColE1 plasmid replication by antisense RNA. , 1991, Trends in genetics : TIG.

[30]  M. Marquet,et al.  Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. , 1995, Human gene therapy.

[31]  H. Blanch,et al.  Recombinant Protein Expression in High Cell Density Fed-Batch Cultures of Escherichia Coli , 1992, Bio/Technology.

[32]  E. Wright,et al.  Dual-origin plasmids containing an amplifiable ColE1 ori; temperature-controlled expression of cloned genes. , 1986, Gene.

[33]  S. Falkow,et al.  Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. , 1977, Gene.

[34]  P. Felgner.  Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides , 1990 .

[35]  R. Kumar,et al.  Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.